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The Brucella species type IV secretion system, encoded by the virB1-12 locus, is required for intracellular
replication and persistent infection in vivo. The requirement of VirB proteins for infection suggests that
they are expressed in vivo and may therefore represent serological markers of infection. To test this idea,
we purified recombinant VirB1, VirB5, VirB11, and VirB12 and tested for their recognition by antibodies
in sera from experimentally infected mice and goats by using an indirect enzyme-linked immunosorbent
assay. Antibody responses to VirB12 but not to VirB1, VirB5, or VirB11 were detected in 20/20 mice
experimentally inoculated with Brucella abortus and 12/12 goats experimentally infected with Brucella
melitensis. The potential use of VirB12 as a serological tool for the diagnosis of brucellosis was evaluated
in the natural bovine host. Serum samples from 145 cattle of known serology (29% negative and 71%
positive) were analyzed for the production of antibody responses to VirB12. One hundred two cattle
samples (70.3%) were positive for antibodies to VirB12, while 43 samples were negative (29.7%). A positive
serological response to VirB12 correlated with positive serology to whole B. abortus antigen in 99% of
samples tested. These results show that VirB12 is expressed during infection of both experimental and
natural hosts of Brucella species, and they suggest that VirB12 may be a useful serodiagnostic marker for
brucellosis.
Brucella strains are the causative agents of brucellosis, which
can affect both animals and humans. The disease is character-
ized by bacterial persistence in the reticuloendothelial system,
including the liver, spleen, and lymph nodes, and infection may
result in abortion in infected ruminants (34). Zoonotic trans-
mission of the bacteria to humans is caused by accidental
contamination from unpasteurized animal products or infected
animals.
The type IV secretion system (T4SS) is encoded by the virB
locus, located on chromosome II, and includes virB1 to virB12
(2, 3). The T4SS of Brucella spp. has been shown to be an
essential virulence factor, and T4SS mutants are highly atten-
uated in tissue culture models of intracellular survival, in the
mouse model of persistent infection (3, 5–8, 10, 14, 23, 30, 32),
and in the goat, a natural host for Brucella melitensis (12). A
functional T4SS is not required for initial colonization in mice
but is required for evasion of immune responses activated
during the first week of infection (25, 27).
Several diagnostic tools are used for the detection of bru-
cellosis. While bacteriological isolation is the most specific
diagnostic test, the frequency of isolation is usually low, and
results are not available immediately. For this reason, serolog-
ical tests are widely used for diagnosis of human and animal
brucellosis (1). Classical serological techniques rely on the
detection of smooth lipopolysaccharide (LPS), but false-posi-
tive reactions may occur due to cross-reactivity with LPS from
other bacteria (21, 22, 33). The shortcomings of the classical
serological tests have sparked increasing interest in finding
alternative antigens to detect brucellosis.
Secreted or cell envelope-associated bacterial proteins are
often antigenic in the context of infection. Proteins associated
with the cell envelope of Brucella species have previously been
shown to elicit antibody responses in both experimentally and
naturally infected animals (4, 17–19, 24, 26). Further, VirB
proteins from other bacteria, including Ehrlichia canis and
Anaplasma marginale, have been shown to be immunogenic (9,
20). Since the Brucella abortus T4SS has been shown to be
expressed during infection and encodes an apparatus that as-
sembles at the surface of the cell, we tested whether the com-
ponents of the T4SS apparatus are immunogenic and whether
responses to these proteins can be used as serological indica-
tors of infection with Brucella species. We have previously
shown that mice infected with B. abortus 2308 produced an
antibody response to the protein encoded by the virB12 gene
(31). In this study, we used purified recombinant VirB1, VirB5,
VirB11, and VirB12 to assess the antibody responses to these
proteins in sera from mice experimentally infected with B.
abortus, from goats experimentally infected with B. melitensis,
and from cattle of known serological status for Brucella.
MATERIALS AND METHODS
Bacterial strains, media, and culture conditions. Escherichia coli cultures were
grown on Luria-Bertani (Difco, Becton Dickinson, Sparks, MD) plates or in
Luria-Bertani broth at 37°C with or without antibiotics. Brucella abortus 2308,
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Brucella melitensis 16M, and isogenic mutant strains were cultured on tryptic soy
agar (Difco, Becton Dickinson, Sparks, MD) or in tryptic soy broth at 37°C on a
rotary shaker. Their characteristics are listed in Table 1. Bacterial inocula for
infection of mice were cultured on tryptic soy agar plus 5% blood. All work with
live Brucella species was performed at biosafety level 3.
Infection of mice. Female C57BL/6J and BALB/c ByJ mice were obtained
from the Jackson Laboratory (Bar Harbor, ME) and used at the ages of 8 to 10
weeks. Mice were held in microisolator cages with sterile bedding and water and
irradiated feed in a biosafety level 3 facility. For infection experiments, groups of
10 to 20 mice were inoculated intraperitoneally with 0.1 ml of phosphate-buff-
ered saline (PBS) containing 5  105 CFU of B. abortus 2308 or an isogenic
virB1-12 mutant (complete deletion of the virB locus). Ten age-matched mice
were injected with PBS. For assaying specific antibody responses, blood samples
were collected from the saphenous vein before infection (infected mice) and
once a week for 10 weeks after infection for both infected and PBS-treated mice.
All animal experiments were approved by the Texas A&M University Laboratory
Animal Care and Use Committee and were conducted in accordance with insti-
tutional guidelines.
Goat serum samples. Twelve serum samples from experimentally infected
goats were used in this study. Animals were infected, and sera were collected, as
described previously by us (12). Briefly, female Angora goats averaging 110 days
of gestation were infected at 1  107 CFU via bilateral conjunctival inoculation,
and sera were collected 8 weeks after infection. Goats (three per group) were
infected with B. melitensis 16M or the BMasp24, BMvirB2 (nonpolar), or
BMcydBA isogenic mutant. Serum samples from 12 naı¨ve goats were also used.
Bovine serum samples. One hundred forty-five serum samples of known se-
rology (as determined by the brucellosis card test and an enzyme-linked immu-
nosorbent assay [ELISA] with whole Brucella antigen) were used in this study.
One hundred three seropositive samples were from the investigators’ specimen
collection. The 42 known negative samples were obtained from male calves
housed at a dairy calf-rearing operation in Texas, since male dairy calves are not
vaccinated against brucellosis.
Purification of GST-VirB1 and GST-VirB5. E. coli BL21 carrying pMO4 (glu-
tathione S-transferase [GST]-VirB1) or E. coli BL21 carrying pAV5.1 (GST-
VirB5) was grown in 20 ml of LB containing 100 g/liter of carbenicillin (LB plus
Carb) at 37°C. Expression of GST-VirB1 or GST-VirB5 was induced with 1 mM
isopropyl--D-thiogalactopyranoside (IPTG) at 37°C. Bacteria were resuspended
in 1 ml of PBS buffer containing 2% Tween 20 and protease inhibitor cocktail
(Sigma). Cells were lysed by sonication and centrifuged, and the supernatant was
mixed with 2 ml of glutathione Sepharose 4B (Amersham Bioscience, Piscat-
away, NJ) beads and incubated for 1 h at 4°C. The slurry was transferred to a
column and washed three times with cold PBS. The protein was eluted by adding
1 ml of elution buffer (0.031 g reduced glutathione in 10 ml of 10 mM Tris-HCl
[pH 8.0]). GST-VirB1 and GST-VirB5 were concentrated using Amicon Ultra-15
(Millipore) concentration tubes.
Removal of the GST tag from VirB1 and VirB5. To avoid measuring serolog-
ical responses to the GST moiety of GST fusion proteins, the GST tag was
removed from GST-VirB1 and GST-VirB5 by incubation with thrombin at room
temperature for 2 h. The reaction mixture was mixed with 1 ml of glutathione
Sepharose 4B (Amersham Bioscience, Piscataway, NJ) beads and incubated for
1 h at 4°C. The slurry was transferred to a column and washed once with cold
PBS (the wash contained the protein of interest). VirB1 and VirB5 were con-
centrated using Amicon Ultra-15 (Millipore) concentration tubes and were di-
alyzed twice against PBS (pH 7.4).
Purification of recombinant VirB11. Strep-VirB11 was purified according to
the manufacturer’s (IBA, Germany) protocol. Briefly, E. coli BL21 carrying
pT7-7Strep::virB11 was grown for 16 h in 2 liters of LB plus Carb at 37°C. On the
following day, expression of Strep-VirB11 was induced with 1 mM IPTG for 16 h
at room temperature. Bacteria were resuspended in 40 ml of washing buffer with
0.5 mM phenylmethylsulfonyl fluoride. Bacteria were lysed with a French press
and pelleted twice at 11,000 rpm, and the supernatant was transferred to a 5-ml
column of streptactin beads (IBA) that was equilibrated with 2 column volumes
(CV) of buffer W (100 mM Tris-HCl [pH 8], 150 mM NaCl, 1 mM EDTA). The
beads were washed twice with 5 CV of buffer W, and the protein was eluted with
6 0.5 CV buffer E (buffer W plus 2.5 mM desthiobiotin). Strep-VirB11 was
concentrated using Amicon Ultra-15 (Millipore) concentration tubes and was
dialyzed twice against PBS (pH 7.4).
Purification of recombinant VirB12. E. coli BL21 carrying pDS1 (His6-
VirB12) was grown in 20 ml of LB plus Carb at 37°C. Expression of His6-VirB12
was induced with 1 mM IPTG at 37°C. VirB12 was purified under denaturing
conditions using reagents from Qiagen (Valencia, CA). Briefly, after induction,
cells were lysed with lysis buffer (100 mM NaH2PO4, 10 mM Tris-HCl, 8 M urea
[pH 8.0]), passed through a column, washed with wash buffer (100 mM
NaH2PO4, 10 mM Tris-HCl, 8 M urea [pH 6.3]), and eluted with elution buffer
(100 mM NaH2PO4, 10 mM Tris-HCl, 8 M urea [pH 4.5]). VirB12 was concen-
trated using Amicon Ultra-15 (Millipore) concentration tubes and was dialyzed
twice against PBS, pH 7.4.
Detection of VirB12-specific IgG in serum samples. The presence of antibody
specific for the recombinant B. abortus VirB12 protein in the sera of mice, goats,
and cattle was determined by an indirect ELISA. Nickel-nitrilotriacetic acid
HisSorb plates from Qiagen (Valencia, CA) were coated with 100 ng of His-
VirB12 per well in carbonate buffer (pH 9.6), and plates were incubated at 4°C
overnight. After a wash with PBS and 0.05% Tween 20 (PBS-T), mouse serum
samples (1:100), goat serum samples (1:16,000), or bovine serum samples (1:
16,000) were diluted in PBS-B for mouse samples (PBS, 0.05% Tween 20, and
2% bovine serum albumin) or PBS-G for goat and bovine samples (PBS, 0.05%
Tween 20, and 2% gelatin) and were incubated at 37°C for 1 h. After a wash with
PBS-T, the reactivity was measured using horseradish peroxidase-conjugated
anti-mouse (1:1,000; BD Pharmingen), anti-goat (1:5,000; Jackson Immuno-
Research), or anti-bovine (1:5,000; Jackson ImmunoResearch) immunoglobulin
G (IgG) by incubating the plates at 37°C for 1 h. The reaction was developed with
Sigma Fast o-phenylenediamine dihydrochloride tablet sets. The resulting color
was read at 450 nm with an ELISA microplate reader (Bio-Rad model 680). Data
points are the averages of duplicate dilutions, and each measurement was per-
formed twice.
Detection of VirB1-specific, VirB5-specific, and VirB11-specific IgG. The pres-
ence of antibody specific for the recombinant proteins VirB1, VirB5, and VirB11
of Brucella abortus in the sera of mice, goats, and cattle was determined by
ELISA. MaxiSorp plates from Qiagen (Valencia, CA) were coated with 100 ng
of VirB1, VirB5, or VirB11 per well in carbonate buffer (pH 9.6), and plates were
incubated at 4°C overnight. ELISA was performed as described above. Data
points are the averages of duplicate dilutions, and each measurement was per-
formed twice.
Detection of Brucella-specific IgG. The presence of antibody specific for whole-
cell antigen of B. abortus in the sera of mice, goats, and cattle was determined by
ELISA. MaxiSorp plates from Qiagen (Valencia, CA) were coated with 100 l
formalin-killed whole B. abortus (1 g/ml) in carbonate buffer (pH 9.6), and
plates were incubated at 4°C overnight. Mouse serum samples were diluted
1:100, while goat and cattle samples were measured at a dilution of 1:16,000.
ELISAs were performed as described above. Data points are the averages of
duplicate dilutions, and each measurement was performed twice.
TABLE 1. Bacterial strains and plasmids
Strain or plasmid Relevant characteristic(s) Source orreference
Strains
E. coli BL21(DE3) F ompT gal [dcm] [lon]
hsdSB(rB
 mB
) DE3
29
Brucella abortus
2308 Bovine isolate B. Deyoe
ADH4 virB1-12::Km 8
Brucella melitensis
16M Wild type 13
BMasp24 asp24 13
BMvirB2 virB2 (nonpolar) 13
BMcydBA cydBA 12
Plasmids
pGEX-4T-2 Apr, N-terminal GST tag,
lacIq
Pharmacia
pAV5.1 VirB5 cloned into pGEX-4T-1 8
pMO4 VirB1 cloned into pGEX-4T-2 8
pIVEX2.4bNdeI Apr, T7 promoter, N-terminal
six-His tag
Roche
pDS1 VirB12 cloned into
pIVEX2.4bNdeI
31
pT7-7Strep::VirB11 VirB11 cloned into pT7-
7Strep
11
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Brucellosis card test. To check the serology status of the goat and cattle
samples, the brucella card test (obtained from National Veterinary Service Lab-
oratories, Ames, IA) was performed according to the manufacturers’ recommen-
dations.
Statistical analysis. For determination of statistical significance between ex-
perimental groups and naı¨ve groups, Student’s t test was performed on the data.
A P value of 0.05 was considered significant.
RESULTS
B. abortus-infected mice develop antibody responses specific
for VirB12 but not for VirB1, VirB5, or VirB11. To determine
whether VirB1, VirB5, VirB11, and VirB12 can serve as sero-
logical markers of infection with Brucella spp., we assayed the
antibody responses of infected mice for IgG specific for VirB1,
VirB5, VirB11, and VirB12. Serum samples were obtained
from mice infected with either B. abortus 2308 or the virB1-12
mutant (a mutant strain carrying a complete deletion of the
virB locus) or from age-matched uninfected controls. We have
previously shown that for B. abortus-infected mice, the level of
IgG specific for VirB12 increased over that for naı¨ve mice
starting at 3 weeks after infection (with the highest response at
weeks 8 to 10), while that for mice infected with a virB12
mutant (in which only virB12 was deleted) did not differ from
the preinoculation level (31). The results in Fig. 1 show that at
week 9 after infection, levels of IgG-specific for VirB1, VirB5,
and VirB11 in preinfection samples or samples from naı¨ve
age-matched mice did not differ from those for mice infected
with either 2308 or the virB1-12 mutant. When mice were
infected with the virB1-12 mutant, levels of VirB12-specific
IgG did not differ from those in preinfection samples or age-
matched naı¨ve mice. VirB12-specific IgG levels did, however,
increase in mice infected with B. abortus 2308 (wild type) over
those in naı¨ve mice, as previously described (31). These results
indicate that VirB12 elicits an antibody response during infec-
tion of mice, while VirB1, VirB5, and VirB11 do not.
VirB12, but not VirB1, VirB5, or VirB11, is immunogenic in
goats. To determine whether VirB1, VirB5, VirB11, and
VirB12 elicited antibody responses in a natural host for Bru-
cella, we obtained sera from 12 goats experimentally infected
with B. melitensis 16M or its isogenic mutant BMasp24,
BMvirB2 (nonpolar), or BMcydBA (12) and sera from 12
naı¨ve goats. The levels of IgG specific for VirB1 (Fig. 2A),
VirB11 (Fig. 2B), or VirB5 (Fig. 2C) determined by ELISA did
not differ between naı¨ve goats and goats infected with either
wild-type B. melitensis 16M or any of the mutant strains. In
contrast, for all four groups of animals infected with B. meliten-
sis strains, the levels of IgG-specific for VirB12 (Fig. 2D) in-
creased significantly above those measured for naı¨ve goats.
These results indicate that VirB12 is expressed in vivo and
generates a host response during infection of goats, while
VirB1, VirB5, and VirB11 do not appear to elicit antibody
responses.
To correlate serological responses to VirB12 with responses
to whole-cell antigen, we performed ELISA on the goat serum
samples using whole-cell Brucella antigen (Fig. 3A). The serol-
ogy response to Brucella IgG was confirmed with the brucel-
losis card test. Goats infected with B. melitensis virB2 (non-
polar) did not exhibit IgG responses to whole-cell Brucella
antigen, while for goats infected with 16M or the asp24 mu-
tant and for two of the goats infected with the cydBA mutant,
anti-Brucella IgG levels increased over those for naı¨ve controls,
in agreement with previous results reported by Kahl-Mc-
Donagh et al. (12).
The correlation between levels of IgG specific for whole-cell
Brucella antigen and VirB12-specific IgG is shown in Fig. 3B.
Three goats infected with B. melitensis virB2 and one goat
infected with B. melitensis cydBA did not develop high levels
of Brucella-specific IgG antibody but produced high levels of
anti-VirB12 antibody. The remaining infected goats generated
both a high Brucella-specific IgG response and a high VirB12-
specific response. For all 12 infected goats, positive antibody
responses to VirB12 were observed.
Cattle seropositive for Brucella also develop an immune
response to VirB12. To explore the potential of VirB12 as a
serological marker of infection in cattle, we measured VirB12-
specific IgG by ELISA in 145 cattle samples of known B.
abortus serology (Fig. 4). We obtained 42 seronegative and 103
seropositive samples. In serum samples from 102 cattle, IgG
specific for VirB12 was detected, with a mean A450 of 0.792 	
FIG. 1. Detection of anti-VirB antibodies in sera from mice experimentally infected with wild-type Brucella abortus 2308 or its virB1-12
isogenic mutant. Ten to 20 mice were infected intraperitoneally with 2308 or a virB1-12 mutant. Blood was collected before infection and 9 weeks
after infection. Ten age-matched mice were treated with PBS, and blood was collected 9 weeks later. Antibodies specific for VirB1, VirB5, VirB11,
and VirB12 (
-VirB1, 
-VirB5, 
-VirB11, and 
-VirB12) were detected by ELISA. Data are presented as the A450 of a 1:100 dilution of serum.
Each bar indicates the average 	 standard deviation of triplicate samples. ND, not determined. Asterisk indicates statistical significance,
determined by Student’s t test. A P value of 0.05 was considered significant.
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0.221. For the 43 cattle samples showing no response to
VirB12, the mean A450 was 0.061 	 0.046. The correlation
between IgG responses specific for Brucella whole-cell antigen
and for VirB12 is shown in Fig. 4. One hundred two samples
(70.3%) were serologically positive for both Brucella and
VirB12. Forty-two samples (29%) were serologically negative
for both whole-cell antigen and VirB12. One animal (0.7%)
showed a seropositive result for whole Brucella antigen, but no
VirB12-specific IgG was detected. Overall, serological results
for whole-cell antigen and VirB12 were concordant for 99% of
samples.
DISCUSSION
This study was undertaken to determine whether individual
proteins encoded by the virB locus, which assemble to form a
secretion apparatus at the surface of the bacterium, are immu-
nogenic and whether serological responses to these proteins
can be used for detection of brucellosis.
We purified recombinant VirB1, VirB5, VirB11, and VirB12
antigens and evaluated their potential use for the serological
diagnosis of brucellosis by ELISA. Evidence of VirB12 expres-
sion (Fig. 1) was detected in mice infected with B. abortus: an
IgG response specific for VirB12 was elicited after infection
with B. abortus 2308 but not after infection with a mutant
lacking the entire virB locus. The cell surface localization of
VirB12 may contribute to its immunogenicity, as well as the
fact that it is a predicted lipoprotein. VirB1, VirB5, and
VirB11 also assemble in the membrane of the bacterium (16,
28), but we could not find evidence of specific antibody re-
sponse against these proteins in the mouse or the goat model.
One possible explanation for this result that we cannot exclude
is that the recombinant VirB1, VirB5, and VirB11 antigens
used for indirect ELISA were not in their native conforma-
tions, which would negatively impact the performance of our
detection assay. However, a lack of immunogenicity of VirB1
and VirB5 could benefit Brucella during infection, since in the
closely related bacterium Agrobacterium tumefaciens, these two
proteins have been shown to be part of a pilus structure that
protrudes from the bacterial surface and is therefore exposed
to the immune system (15).
The BMasp24, BMvirB2, and BMcydBA mutants used
in our study have been assessed as vaccine candidates in the
goat and mouse models of infection (12, 13). Both the
BMasp24 and BMvirB2 mutants have shown promise as safe
vaccine candidates in mouse and goat models. BMasp24 was
able to colonize the maternal tissues but not the fetal tissues
and cause seroconversion in goats, while BMvirB2 was not
capable of colonizing maternal or fetal tissues and did not
cause seroconversion. The BMcydBA mutant was as virulent
in the pregnant goat model as 16M (12).
Goats infected with B. melitensis 16M or the BMasp24,
BMvirB2, or BMcydBA mutant elicited a response specific
for VirB12, but not for VirB1, VirB5, or VirB11. BMvirB2 is
FIG. 2. Analysis of anti-VirB (
-VirB) antibodies in sera from 12 goats experimentally infected with wild-type B. melitensis 16M or one
of its isogenic mutants BMvirB2, BMasp24, or BMcydBA and from 12 uninfected controls. Blood was collected 8 weeks after infection,
and levels of IgG specific for VirB1, VirB5, VirB11, and VirB12 in serum were determined by ELISA. Data are presented as the A450 of a
1:16,000 dilution of serum. Each bar indicates the average 	 standard deviation for three goats per infected group assayed in triplicate. The
uninfected group contains 12 goats. The horizontal line in each graph represents the background reactivity of uninfected goats. Asterisks
indicate statistically significant differences between groups of infected and naı¨ve goats, determined by Student’s t test. A P value of 0.05
was considered significant.
VOL. 15, 2008 VirB12 IS A SEROLOGICAL MARKER OF BRUCELLA INFECTION 211
 o
n
 Septem
ber 12, 2018 by guest
http://cvi.asm
.org/
D
ow
nloaded from
 
a nonpolar mutation of VirB2; thus, VirB3 to VirB12 are
expected to be expressed during infection (8). Goats infected
with BMvirB2 did not seroconvert to whole-cell Brucella an-
tigen (Fig. 3) (12) but exhibited a strong VirB12 response. One
of the goals for the development of vaccines and diagnostic
tools for brucellosis is a test that can distinguish between vac-
cinated and naturally infected animals. Our results show the
potential of using VirB12 for such a goal, since BMvirB2 was
found to be a safe vaccine with no seroconversion by using the
brucellosis card test and whole-cell ELISA but elicited an
FIG. 3. (A) Brucella-specific (
-Brucella) IgG in sera from 12 goats experimentally infected with wild-type Brucella melitensis 16M or its isogenic
mutant BMvirB2, BMasp24, or BMcydBA and from 12 uninfected controls. Blood was collected 8 weeks after infection, and levels of
Brucella-specific IgG in serum samples were determined by ELISA and the brucellosis card test. Data are presented as the A450 of a 1:16,000
dilution of serum. Each bar indicates the average 	 standard deviation for 3 goats per infected group or 12 goats per uninfected group, assayed
in triplicate. Asterisks indicate that differences between groups of infected and naı¨ve goats, determined by Student’s t test, are statistically
significant. A P value of 0.05 was considered significant. (B) Correlation between Brucella-specific IgG and VirB12-specific (
-VirB12) IgG in
goats. Each dot represents both the level of Brucella-specific IgG and the level of Brucella-specific anti-VirB12 for one goat. Horizontal and vertical
lines represent the background reactivities for uninfected goats (A450, 0.2). Data points above the dashed line represent goats with positive card
test results, while points below this line represent animals with negative card test results.
FIG. 4. Analysis of anti-VirB12 (
-VirB12) IgG and Brucella-specific (
-Brucella) IgG in sera from cattle infected with Brucella abortus. The
lines represent the background reactivities for uninfected and unvaccinated cattle, as determined by ELISA and the brucellosis card test. Data are
presented as the A450 of a 1:16,000 dilution of serum.
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elevated VirB12 response when an ELISA with recombinant
purified VirB12 was used to assay infection.
A second goal of the present study was to assess the poten-
tial diagnostic utility of VirB12 in natural hosts of Brucella. We
obtained 145 cattle serum samples of known serology (42 se-
ronegative [29%] and 103 seropositive [71%]). Serology status
was checked by both the brucellosis card test and whole-cell
Brucella antigen ELISA.
As shown in Fig. 4, antibodies to VirB12 were detected in
70.3% (102 of 145) of bovine serum samples tested, while
29.7% of the samples did not give a response to VirB12. One
of the 145 cattle samples was serologically positive for Brucella
but negative for antibodies specific to VirB12. Serological tests
for brucellosis may yield false-positive results for cattle vacci-
nated with B. abortus S19 or exposed to gram-negative bacteria
with LPS O-chains similar to those of Brucella, such as Yersinia
enterocolitica O:9. The cross-reactivity between Y. enterocolitica
O:9 and Brucella is due to a strong similarity of the LPS
O-chains (21, 33). We do not know if this animal showed
serological reactivity to Brucella due to cross-reactivity with Y.
enterocolitica O:9 or other bacteria, such as E. coli O157:H7, a
frequent colonizer of cattle. Since we did not detect seroreac-
tivity to VirB12, either this animal may have been infected and
did not respond to VirB12 or it had a serological cross-reaction
to whole cells elicited by bacteria other than Brucella. Based on
the information at hand, we are unable to distinguish between
these two possibilities.
In summary, this study shows that antibodies to B. abortus
VirB12 can be identified in mice, goats, and cattle. One hun-
dred percent of the experimentally infected mice and goats
generated specific responses to VirB12, including those in-
fected with mutants shown to be promising vaccine candidates
(12, 13). These results encourage further investigation with
patient samples to determine whether detection of humoral
responses to VirB12-specific immune responses can be used
for the diagnosis of human brucellosis.
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